Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Sirona Biochem Corp > new tweet from SBM
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(65)
•••
Comment by MirrorWorldManon Jun 21, 2022 12:09pm
171 Views
Post# 34771523

RE:RE:RE:RE:RE:RE:RE:RE:new tweet from SBM

RE:RE:RE:RE:RE:RE:RE:RE:new tweet from SBMIt is difficult to understand why Howie wants to still to business with Wannabang,  Afterall, it took 10 years to do anything with our SGLT2 and then that company dumped us for generics.  They must of know of the pending favourable generic government policies and strung us along.  Now they are saying we go to pets.  Whats stopping anyone from using a generic SGLT2 in pets as well.  I would dump them as they dump us.  Businesses are moving out of China now into more favourable EU manufacturing enviroments  and Howie wants to continue with a company proven to abrasive to our needs?  Crazy
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities